{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:18:24Z","timestamp":1772446704292,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104525","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:48:33Z","timestamp":1772444913000},"source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroid-Resistant Secondary Immune Thrombocytopenia in Smoldering Multiple Myeloma Successfully Treated With Eltrombopag: A Case Report"],"prefix":"10.7759","author":[{"given":"Ryutaro","family":"Tominaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbacli.2016.05.004","article-title":"Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"6","author":"Shimanovsky A","year":"2016","unstructured":"Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016, 6:12-8. 10.1016\/j.bbacli.2016.05.004","journal-title":"BBA Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03672-1","article-title":"Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition","volume":"119","author":"Kashiwagi H","year":"2024","unstructured":"Kashiwagi H, Kuwana M, Murata M, et al.. Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition. Int J Hematol. 2024, 119:1-13. 10.1007\/s12185-023-03672-1","journal-title":"Int J Hematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282ab98c7","article-title":"The epidemiology of immune thrombocytopenic purpura","volume":"14","author":"Fogarty PF","year":"2007","unstructured":"Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007, 14:515-9. 10.1097\/MOH.0b013e3282ab98c7","journal-title":"Curr Opin Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero F","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al.. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009, 113:2386-93. 10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos MV","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, et al.. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020, 10:102. 10.1038\/s41408-020-00366-3","journal-title":"Blood Cancer J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-015222","article-title":"Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience","volume":"109","author":"Mazzucconi MG","year":"2007","unstructured":"Mazzucconi MG, Fazi P, Bernasconi S, et al.. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood. 2007, 109:1401-7. 10.1182\/blood-2005-12-015222","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000574","article-title":"Immune thrombocytopenia: recent advances in pathogenesis and treatments","volume":"5","author":"Audia S","year":"2021","unstructured":"Audia S, Mah\u00e9vas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. Hemasphere. 2021, 5:e574. 10.1097\/HS9.0000000000000574","journal-title":"Hemasphere"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2000.00125.x","article-title":"Multiple myeloma and immune thrombocytopenia","volume":"22","author":"Gupta V","year":"2000","unstructured":"Gupta V, Hegde UM, Parameswaran R, Newland AC. Multiple myeloma and immune thrombocytopenia. Clin Lab Haematol. 2000, 22:239-42. 10.1046\/j.1365-2257.2000.00125.x","journal-title":"Clin Lab Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1012","article-title":"Multiple myeloma with concurrent immune thrombocytopenic purpura","volume":"14","author":"Sarfraz H","year":"2020","unstructured":"Sarfraz H, Anand K, Liu S, Shah S. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancermedicalscience. 2020, 14:1012. 10.3332\/ecancer.2020.1012","journal-title":"Ecancermedicalscience"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004981","article-title":"Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma","volume":"11","author":"Diogo C","year":"2024","unstructured":"Diogo C, Fernandes C, Cunha S, Luz L, Santos JG, Monteiro JR. Can you diagnose immune thrombocytopenia in myeloma? A case of thrombocytopenia in a patient with multiple myeloma. Eur J Case Rep Intern Med. 2024, 11:004981. 10.12890\/2024_004981","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref11","article-title":"ITP revealing a SMM: a case report and review of the literature","volume":"4","author":"Rakez R","year":"2021","unstructured":"Rakez R, Chefaii A, Hadhri R, Sassi MB, Boukhriss S, Laatiri MA. ITP revealing a SMM: a case report and review of the literature. J Clin Images Med Case Rep. 2021, 4:16-8.","journal-title":"J Clin Images Med Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01094-w","article-title":"Smoldering multiple myeloma presenting as immune thrombocytopenia","volume":"35","author":"Jain A","year":"2019","unstructured":"Jain A, Khunger JM, Kapahtia S, Prasad P, Gupta DK, Chaudhry S. Smoldering multiple myeloma presenting as immune thrombocytopenia. Indian J Hematol Blood Transfus. 2019, 35:565-6. 10.1007\/s12288-019-01094-w","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.03.2009.1715","article-title":"Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer","volume":"2009","author":"Siniscalchi A","year":"2009","unstructured":"Siniscalchi A, Stasi R, Fratoni S, de Fabritiis P, Caravita T. Management of immune thrombocytopoenia in a patient with newly-diagnosed smouldering myeloma and colorectal cancer. BMJ Case Rep. 2009, 2009:23-5. 10.1136\/bcr.03.2009.1715","journal-title":"BMJ Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001617","article-title":"Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study","volume":"134","author":"Visco C","year":"2019","unstructured":"Visco C, Rodeghiero F, Romano A, et al.. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood. 2019, 134:1708-11. 10.1182\/blood.2019001617","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4927.4927","article-title":"Four cases of lenalidomide-associated immune thrombocytopenia","volume":"128","author":"Pompa A","year":"2016","unstructured":"Pompa A, Guidotti F, Gregorini AI, Goldaniga MC, Rossi FG, Baldini L, Cortelezzi A. Four cases of lenalidomide-associated immune thrombocytopenia. Blood. 2016, 128:4927. 10.1182\/blood.V128.22.4927.4927","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/638020","article-title":"Lenalidomide-associated ITP","volume":"2011","author":"Herold CI","year":"2011","unstructured":"Herold CI, Gasparetto C, Arepally GM. Lenalidomide-associated ITP. Case Rep Hematol. 2011, 2011:638020. 10.1155\/2011\/638020","journal-title":"Case Rep Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.57352\/ijm.8.1_1","article-title":"Development of unexpected severe thrombocytopenia just after initiating lenalidomide: possible involvement of an immunologic mechanism","volume":"8","author":"Meguri Y","year":"2018","unstructured":"Meguri Y, Kambara Y, Yamamoto A, Masunari T, Sezaki N, Kiguchi T. Development of unexpected severe thrombocytopenia just after initiating lenalidomide: possible involvement of an immunologic mechanism. Int J Myeloma. 2018, 8:1-3. 10.57352\/ijm.8.1_1","journal-title":"Int J Myeloma"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8825618","article-title":"Lenalidomide-associated immune thrombocytopenia: a case report and review of the literature","volume":"2020","author":"Forehand Iii W","year":"2020","unstructured":"Forehand Iii W, Ajebo G, Toscano M, Jillella A, Dainer P. Lenalidomide-associated immune thrombocytopenia: a case report and review of the literature. Case Rep Hematol. 2020, 2020:8825618. 10.1155\/2020\/8825618","journal-title":"Case Rep Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12342","article-title":"Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes","volume":"93","author":"Murai K","year":"2014","unstructured":"Murai K, Kowata S, Shimoyama T, Yashima-Abo A, Fujishima Y, Ito S, Ishida Y. Bortezomib induces thrombocytopenia by the inhibition of proplatelet formation of megakaryocytes. Eur J Haematol. 2014, 93:290-6. 10.1111\/ejh.12342","journal-title":"Eur J Haematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial S","year":"2005","unstructured":"Lonial S, Waller EK, Richardson PG, et al.. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005, 106:3777-84. 10.1182\/blood-2005-03-1173","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/465580-corticosteroid-resistant-secondary-immune-thrombocytopenia-in-smoldering-multiple-myeloma-successfully-treated-with-eltrombopag-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:48:34Z","timestamp":1772444914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/465580-corticosteroid-resistant-secondary-immune-thrombocytopenia-in-smoldering-multiple-myeloma-successfully-treated-with-eltrombopag-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.104525","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}